Advances in antithrombotic therapy in patients with valvular heart disease after transcatheter intervention
- VernacularTitle:心脏瓣膜病患者经导管介入治疗后抗栓治疗研究进展
- Author:
Yanhai MENG
1
;
Lulu LI
1
;
Yanbo ZHANG
1
Author Information
1. Adult Surgery ICU, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100037, P. R. Chin
- Publication Type:Journal Article
- Keywords:
Anticoagulation;
thromboembolism;
transcatheter aortic valve implantation;
transcatheter mitral valve implantation;
review
- From:
Chinese Journal of Clinical Thoracic and Cardiovascular Surgery
2024;31(09):1363-1368
- CountryChina
- Language:Chinese
-
Abstract:
As technology advances, current evidence supports the use of devices for valvular heart disease interventions, including transcatheter aortic valve implantation, transcatheter mitral or tricuspid valve repair, and transcatheter mitral valve implantation. These procedures require antithrombotic therapy to prevent thromboembolic events during the perioperative period, and these therapies are associated with an increased risk of bleeding complications. To date, there are challenges and controversies regarding how to balance the risk of thrombosis and bleeding in these patients, and therefore the optimal antithrombotic regimen remains unclear. In this review, we summarize the current evidence for antithrombotic therapy after transcatheter intervention in patients with valvular heart disease and highlight the importance of an individualized approach in targeting these patients.
